Elan and partner Biogen said today their drug Tysabri has been approved in New Zealand for treatment of the relapsing remitting form of multiple sclerosis.
The approval was based on favourable results of a two-year late-stage trial of the medicine, the companies said in a release, noting that an estimated 4,000 people in New Zealand are affected by MS.
The drugmakers said clinical data show the medicine, after two years of use, reduced by 68% the annual number of relapses in flare-ups of the disease compared to placebo and reduced the risk of disability progression by 42%.
